antiretroviral treatment or switched to dual therapy based on lamivudine and dolutegravir between June 2018 and September 2019 were included. Study variables were age, sex, date and reason for the change, duration of treatment, viral load (CV, copies/mL), CD4 and CD8 cells (cells/mL) before and after the change and on the date of the last available analysis, previous therapy, glomerular filtration rate (GFR) (mL/min), and levels of cholesterol (mg/dL), low density lipoprotein (LDL, mg/dL) and triglycerides (mg/dL). Results Nine patients (66.66% men) with a mean age of 49 years (30-58), 3 of whom were naive patients (33.33%) were analysed. Effectiveness was 100% of patients who achieved CV <50 copies at 4-6 weeks, maintaining the virological response for an average of 26 weeks. CD4 and CD8 counts increased significantly from 690 to 805 and 910 to 943, respectively. The lipid profile showed differences in LDL from 170 to 120. A significant decrease in GFR was observed from 102 to 87. The annual cost saw a decrease of 1690C ¼ /patient/ year. Conclusion and relevance Simplification to dual therapy was a safe and effective option that allowed optimisation of the resources against triple therapy.

No abstract

No abstract

DAL allowed immediate patient discharge in 73% of patients.The overall clinical success rate of DAL was 89%. Adverse events, mainly mild in intensity, were reported in six patients. The total cost of DAL was C ¼ 62 179. Overall, DAL was estimated to reduce hospitalisation by 273 days, with an estimated overall cost reduction of C ¼ 67 466 (C ¼ 3551 per patient). Conclusion DAL appears to be an effective and safe therapy in several serious gram-positive infections. Its use to facilitate hospital discharge can potentially lead to cost savings.

No abstract